Tagged with EG

Spain Staffan Schüberg, CEO of Esteve, highlights the restructure of the company as it moves towards its new age of being a truly innovative pharmaceutical company on a global level. Furthermore, he highlights the international strategy and the role the US market will play in the future, as well as his…

Opinion Chester “Chip” Davis, Jr, the President and CEO of the Association for Accessible Medicines (AAM) in the US urges Congress to avoid restricting out-of-court drug patent settlements and to move away from anti-competitive practices that work to restrict patients access to generics and biosimilars.    Recent legislation introduced in the US Senate would…

Opinion Our contributor at large, David Crean, Managing Director for Objective Capital Partners, attended J.P. Morgan’s 2019 Health Care Investor Conference, one of the biggest events in the life sciences calendar and a fantastic indicator of what is to come in healthcare for the year ahead. Here, Crean gives us the inside scoop. …

Spain Sergio Rodriguez, CEO of Pfizer Spain, highlights the strength of the affiliate and the importance for the company in Europe, as well as the key areas that are driving their growth. Furthermore, he gives an overview of the need for innovative companies to partner with key stakeholders and illustrates what…

Korea Rana Azfar, vice-president & general manager of Novo Nordisk Korea offers his impressions of the Korean market since moving from Pakistan. Azfar discusses how the most innovative insulin products have propelled Novo Nordisk forward in Korea, and how Novo Nordisk is working with patients and doctors to address the misconceptions…

Korea Yong Zu Kim, founder and CEO of Lego Chem, discusses his company’s two areas of focus, anti-infectives and antibody drug conjugates. Dr Kim explains how his strategy has changed from solely licensing out to adopting in-house development and offers his view on the potential consolidation within the biotech sector in…

Korea Dr BG Rhee, CEO of SCM Lifescience discusses their patented proprietary subfraction technology to extract high purity cell cultures, and the impact this will have on the efficacy, cell differentiation ability, and cost of stem cell treatments. Dr Rhee also provides his assessment of the regulatory framework for stem cells…

France Thierry Hulot, president biopharma of Merck France, explains how France has become more open to diversity, while still needing significant reforms in the healthcare sector to remain competitive. He also shares insights into his career and the learnings from the Levothyrox case.   Overall, we are a very important branch…

Spain Marieta Jiménez, president and general manager of Merck Spain, highlights her three top priorities: innovation, science and technology, and women’s equality. Furthermore, she gives an overview of the need for better collaboration for long-term sustainably of the Spanish healthcare system and breaks down the role of the ClosingGap cluster to…

France Pascal Joly, general manager of Medac France, explains how he and his executive team have built the French affiliate from scratch, while highlighting the importance of gaining swift market access and having a diverse product portfolio.   Lyon carries a number of strategic advantages: economically speaking, office spaces are significantly…

China Tony Au, general manager of AbbVie China, shares the key milestones for the affiliate in the past six years, the strong foundation he has built for AbbVie in China, the mission of AbbVie to be the most reliable pharmaceutical company in China, and the exciting pipeline of innovative products and…

Turkey Seizing the cost competitiveness of the Turkish market and the government’s nurturing of local manufacturing, Turkish companies are looking to harness their geographic positioning and export to developed and developing markets alike.   We did not shy away from entering the most advanced healthcare ecosystems. Barış Özyurtlu, General Manageger, Berko Ilac.…